NYSE: ELAN

Elanco Animal Health (ELAN) Stock Analysis & Forecast

Nov 13 close

$26.78+0.28 (+1.1%)

Gekko Brief

AI summaryNov 9 close

Elanco's third-quarter results drove this week's move, with revenue up 11% to $1.265 billion and organic constant currency growth of 9%, led by demand for pet health products Zenrelia and Credelio Quattro and higher prices across the portfolio. The company raised its full-year outlook and reported net income of $18 million, a marked improvement from a loss a year earlier, while also lowering gross debt by $216 million in the quarter. Management has continued to discuss these results publicly, including at the UBS Global Healthcare Conference on 9 November.

Shares closed at $26.84, up 4.3% on the day, sitting above both the 50-day average of $23.19 and the 200-day average of $23.81, with one-month returns of 17.1% and one-year returns of 24.7%. The GekkoIndex reads 41.9, placing ELAN in the Distribution zone, down 8.8 points over five sessions. Price sits 16.7% above Gekko Fair Value of $23.00.

The next earnings date falls on 23 February 2027, outside a typical 20-trading-day holding window. Over the last 90 days, insiders made 3 open-market purchases totaling $1,139,293, and one trailblazer holder is recorded. Analyst coverage from 13 firms shows 11 buy and 2 hold ratings, with a consensus target of $30.23. Seasonality over the next 20 trading days has averaged -0.8% across 5 years, rising in 2 of them, a pattern worth noting against the stock's typical 20-day move of 7.5%.

Written by AI from the Nov 9, 2026 close and checked automatically against the figures on this page.

Elanco Animal Health price vs fair value

$26.78$23.70Nov ’25May ’26Nov ’26
Close $26.78200-day averageGekko Fair Value $23.70

Elanco Animal Health quick facts

Market cap
$13.39B
P/E ratio
—
Forward P/E
19.6
EPS, TTM
−$0.30
Revenue, TTM
$5.15B
Profit margin
-2.9%
Dividend yield
—
Beta
1.72
Volume
5.38M avg 5.54M
1-year return
+21.5%
Typical daily move
±3.7%
Typical 20-day move
±7.5%
50-day average
$23.38
200-day average
$23.86
Next earnings
Feb 23 before open
Shares outstanding
499.8M
52-week range
$19.40$27.98

Elanco Animal Health swing-trade checklist

Elanco Animal Health scores 3 supportive, 2 mixed and 1 headwind across the 6 checklist items with data.

Six things swing traders check before a 20-day hold, read from the latest data.

3 supportive2 mixed1 headwind

  • Trendmixed

    Averages disagree

    Close $26.78 sits between the 50-day ($23.38) and 200-day ($23.86) averages, or the averages disagree.

    See the chart
  • GekkoIndexmixed

    45.8, Neutral

    Reading 45.8 is in the Neutral zone.

    See the GekkoIndex
  • Fair valueheadwind

    13.0% above

    Price is 13% above Gekko Fair Value (more than 5% above).

    See fair value
  • Smart moneysupportive

    Leans bullish

    Last 90 days: 2 open-market insider purchases.

    See smart money
  • Earnings risksupportive

    Reports in 100 days

    Next report Feb 23, 2027, 100 days away — outside a typical 20-trading-day hold.

    See earnings
  • Seasonalitysupportive

    +0.2% on average

    From this point in the calendar, the next 20 trading days averaged +0.2% over 5 years, rising in 3 of them.

    See seasonality

A description of current data, not a recommendation. How this page works

Elanco Animal Health stock chart and price history

Elanco Animal Health closed at $26.78 on Nov 13, 2026, +21.5% over the past year, inside a 52-week range of $19.40 to $27.98.

Close50-day average200-day averageVolume
Elanco Animal Health share price, past year, with 50-day and 200-day moving averages and volume$15$20$25DecJan 2026FebMarAprMayJunJulAugSepOctNov26.78

Use the left and right arrow keys to read daily values.

Performance Breakdown

1 month
+13.8%
3 months
+13.4%
6 months
+34.8%
1 year
+21.5%
The full ELAN chart adds GekkoIndex, insider, options, Congress and hedge fund markers, plus TrendCandles™.Open ELAN in Gekko

Follow Elanco Animal Health through every session

Put ELAN on a Gekko watchlist and see its GekkoIndex, Gekko Fair Value and smart money signals update on the chart as they change.

Track ELAN in GekkoFree for 7 days. No credit card required.

About Elanco Animal Health

Elanco Animal Health develops, manufactures, and sells products aimed at keeping pets and farm animals healthy. For dogs and cats, its lineup covers preventive treatments against parasites like fleas, ticks, and worms, sold under names such as Seresto, Advantage, Advantix, and Advocate, alongside medicines for pain, joint disease, ear infections, heart problems, and skin conditions marketed as Galliprant and Claro.

On the livestock side, Elanco makes vaccines, antibiotics, and parasiticides for poultry and aquaculture operations, plus nutritional additives like enzymes, probiotics, and prebiotics meant to support growth and overall health. For cattle, dairy herds, and pigs, it offers vaccines, antibiotics, implants, and parasiticides, including well-known products like Rumensin and Baytril. These goods reach the market through independent distributors, veterinary practices, and a wide range of animal producers spanning dairy and cattle farms to poultry, swine, and aquaculture businesses.

The company was founded in 1954 and is headquartered in Greenfield, Indiana. Its shares trade on the NYSE under the ticker ELAN.

Listed
NYSE
Sector
Health technology
Industry
Biotechnology
Website
elanco.com

Elanco Animal Health GekkoIndex: the smart money zone

Elanco Animal Health’s GekkoIndex — Gekko’s 0 to 100 smart money score — reads 45.8, in the Neutral zone, up 0.3 points over five sessions.

010045.8Neutral

Up 0.3 points over five sessions.

Reading for Nov 13, 2026

What followed past readings in each zone

ZoneReadings5 days10 days20 days50 days
Buying41−0.6%+1.1%+9.7%+8.1%
Accumulation223+1.5%+2.8%+4.1%+8.3%
Neutral (current zone)398+0.2%+0.1%−0.1%+2.0%
Distribution39+0.7%+0.8%+4.5%+7.7%
Selling1Too few readings yet

Average ELAN share-price change over the trading days after each daily reading in its GekkoIndex history. Across every stock Gekko tracks, Neutral readings averaged +0.9% over 20 days. Past behaviour doesn’t guarantee future results.

Neutral zone: No clear directional signal. About the five zones →

See every daily GekkoIndex reading plotted over the ELAN price, zone by zone.Track ELAN in Gekko

Is Elanco Animal Health stock overvalued? Gekko Fair Value

Elanco Animal Health trades 13.0% above Gekko Fair Value of $23.70, so the shares are overvalued on Gekko’s estimate.

Gekko’s own estimate of what Elanco Animal Health shares are worth, recalculated every trading day.

$23.70

Gekko Fair Value, Nov 14, 2026

13.0% Overvalued

At the end of Aug 2026 the price was 23.0% above the estimate.

Gekko Fair ValueShare price, month end
$24$27Aug 2026SepOctNov 2026

How Gekko Fair Value works →

Gekko Fair Value on every chart, with the gap to price updating daily.Open ELAN in Gekko

Elanco Animal Health insider and Congress trading

Insiders filed 2 open-market purchases in Elanco Animal Health worth $1.03M, and no Congress trades were disclosed, in the last 90 days.

Plus buybacks, unusual options and fund positions, each dated to when it became public.

Insider buying last 90 days

$1.03Min 2 open-market purchases

FiledInsiderTypeSharesValue
Aug 21Kurzius Lawrence Erik
director
Purchase40,000$936K
Aug 18Shiv O'Neill
GC AND CORP SEC
Purchase3,998$94K

From Form 4 filings, dated to when each was filed.

Congress trades last 90 days

No trades in ELAN were disclosed by members of Congress in the last 90 days.

From congressional disclosures, which report amounts as ranges.

Congress disclosures for ELAN, plotted on the chart in Gekko.Open ELAN in Gekko

Buybacks

Elanco Animal Health has been buying back its own shares.

Bought back, quarter ended Jun 30, 2026
$34.00M
As a share of market cap
0.25%

From company filings.

Hedge funds and billionaires quarter ended Dec 31

1of the funds Gekko tracks holds ELAN.

0added1opened0trimmed0sold out
Which funds are on each side, name by name.Unlock in Gekko

Elanco Animal Health earnings: next date and track record

Elanco Animal Health reports on Feb 23, 2027, before the open (100 days away), and beat the EPS estimate in 7 of its last 8 reports.

7 of 8reports beat the EPS estimate
±10.1%average move across the report
6 of 8reports followed by a gain

Share-price move across each report

+9.4%Nov ’24+0.2%Feb ’25+29.1%May ’25+19.2%Aug ’25−4.4%Nov ’25+8.4%Feb ’26+4.4%May ’26−5.5%Aug ’26

Last earnings call, Aug 5, 2026 AI summary

What they said
Elanco reported strong Q2 2026 results, with $1.368B revenue (up 10% reported, 8% organic constant currency) driven by U.S. Pet Health and U.S. Farm Animal. Innovation contributed $340M in the quarter and management raised the full-year innovation revenue target to $1.25B. Management beat the high end of guidance for revenue, adjusted EBITDA and adjusted EPS and raised full-year guidance. Adjusted gross margin improved to 58.1% (up 80 bps YoY) and management now expects ~50 bps of gross margin expansion for the year (up from prior 40 bps guidance). Elanco highlighted Zenrelia and Credelio Quattro (Quattro) as primary growth drivers, strong commercial execution across channels, continued international rollouts (Zenrelia in 47 countries; AdTab growth in Europe), and continued investments in DTC marketing to drive share. Working capital discipline and Project Ascend productivity efforts have accelerated net leverage reduction; management reiterated debt paydown as top capital allocation priority until leverage falls below their target range. The company sees durable end-markets (resilient pet owner spend, growing farm/protein demand) and significant runway for its “Big 6” innovations, while continuing to invest behind growth and selectively in M&A.
Guidance
Raised full-year guidance for revenue, adjusted EBITDA and adjusted EPS (no specific dollar or EPS figures disclosed on the call). Raised full-year innovation revenue target to $1.25 billion. Management increased gross margin expansion guidance to ~50 basis points year-over-year (up from prior ~40 bps). Management also stated they are improving year-end net leverage expectations (targeting to get below ~3x net leverage in the medium term) and reiterated that debt paydown remains the number-one use of free cash flow until leverage targets are met.
Risks flagged
Mentioned risks and headwinds: inflationary pressures and elevated inventory costs impacting first-half margin flow-through; ongoing competition in key segments; supply constraints/gating for newly launched biologics (Befrena) while manufacturing ramps; timing/accelerated shipments (e.g., to Middle East) that affect quarter-to-quarter comparability; drought and other macro factors affecting herd expansion and farm-animal demand; and general forward-looking statement cautions (SEC filings).
ReportedEPSSurpriseRevenueSurpriseMove
Aug 5, 2026$0.34
est $0.27
+25.9%$1.37B
est $1.31B
+4.2%−5.5%
May 6, 2026$0.40
est $0.34
+17.6%$1.37B
est $1.28B
+7.4%+4.4%
Feb 24, 2026$0.13
est $0.11
+14.5%$1.14B
est $1.09B
+4.7%+8.4%
Nov 5, 2025$0.19
est $0.13
+46.2%$1.14B
est $1.09B
+4.1%−4.4%
Aug 7, 2025$0.26
est $0.20
+30.0%$1.24B
est $1.09B
+13.9%+19.2%
May 7, 2025$0.37
est $0.30
+23.3%$1.19B
est $1.18B
+1.3%+29.1%
Feb 25, 2025$0.14
est $0.15
−5.8%$1.02B
est $1.21B
−15.7%+0.2%
Nov 7, 2024$0.13
est $0.12
+8.3%$1.03B
est $1.01B
+1.7%+9.4%

“Move” is the close of the first session after the report compared with the close of the last session before it, so it reads the same whether the company reported before the open or after the close.

Elanco Animal Health stock forecast and analyst price targets

Analysts’ average 12-month price target for Elanco Animal Health is $31.00, +15.8% from the last close, from 11 firms rating the stock in the last 90 days.

$31.00consensus 12-month target, +15.8% from the last close
Low $24High $35
Buy9
Hold2
Sell0

Each firm’s latest rating in the last 90 days: 11 firms.

Latest analyst actions

DateFirmRatingTargetvs price
Nov 9Piper SandlerBuy, maintained$30+12.0%
Nov 9J.P. MorganBuy, reiterated$35+30.7%
Nov 9UBSBuy, reiterated$35+30.7%
Nov 9Stifel NicolausBuy, reiterated$33+23.2%
Nov 9KeyBancBuy, reiterated$30+12.0%
−0.1%average 20-day move after past Neutral readings
+0.2%average move over the next 20 trading days in the last 5 years
±3.7%typical daily move, from the 14-day average range

Gekko doesn’t publish price predictions. These are analyst targets and historical base rates, which don’t guarantee future results.

Elanco Animal Health seasonality: the next 20 trading days

Over the next 20 trading days from Nov 14, Elanco Animal Health averaged +0.2% across the last 5 years, rising in 3 of them.

Next 20 trading days, by year

−12.6%2021+1.6%2022+20.5%2023−13.8%2024+2.9%2025

Average move and hit rate

WindowAverageYears higher
Next 5 trading days−0.4%2 of 5
Next 10 trading days−1.9%2 of 5
Next 15 trading days−2.1%2 of 5
Next 20 trading days+0.2%3 of 5
Next 30 trading days+0.5%2 of 5

For scale, ELAN’s typical 20-trading-day move in either direction is about 7.5%.

Elanco Animal Health market cap and key statistics

Elanco Animal Health’s market cap is $13.39B and revenue of $5.15B over the last twelve months.

Valuation

Market cap
$13.39B
Forward P/E
19.6
EPS, TTM
−$0.30
Gekko Fair Value
$23.70

Trading

Volume
5.38M
Avg volume, 20 days
5.54M
52-week high
$27.98
52-week low
$19.40
Shares outstanding
499.8M

Financials

Revenue, TTM
$5.15B
Profit margin
-2.9%
Return on equity
-2.2%
Quarterly earnings growth, YoY
+440.5%

Risk and income

Beta
1.72
Typical daily move
±3.7%
Typical 20-day move
±7.5%

Elanco Animal Health peers

Elanco Animal Health’s 6 largest industry peers by market value, with today’s move, GekkoIndex zone and gap to Gekko Fair Value.

StockTodayGekkoIndex zonevs Fair Value
AMGNAmgen−0.4%Neutral19.9% below
GILDGilead Sciences−0.3%Neutral11.7% above
MRNAModerna−0.7%Neutral21.1% above
NTRANatera−1.8%Accumulation18.6% below
IQVIQVIA−2.4%Accumulation5.0% above
UTHRUnited Therapeutics−0.4%Neutral11.2% below

A peer links to its own page where one exists.

In the Buying zone today

Reporting earnings this week

Popular on Gekko

More stocks in Biotechnology

Elanco Animal Health stock FAQ

What is Elanco Animal Health’s market cap?

Elanco Animal Health’s market cap is $13.39B at the Nov 13, 2026 close of $26.78, with 499.8M shares outstanding.

What is the Elanco Animal Health stock forecast?

The consensus analyst 12-month price target for Elanco Animal Health is $31.00, +15.8% from the last close. Of the 11 firms that rated the stock in the last 90 days, 9 rate it a buy, 2 a hold and 0 a sell. Gekko doesn’t publish price predictions of its own.

Is Elanco Animal Health stock overvalued or undervalued?

On Gekko’s estimate Elanco Animal Health is overvalued: the Nov 13, 2026 close of $26.78 is 13.0% above Gekko Fair Value of $23.70. Gekko Fair Value is recalculated every trading day, and a gap inside 5% either way counts as about fair value.

When does Elanco Animal Health report earnings next?

Elanco Animal Health is expected to report on Feb 23, 2027, before the market opens (100 days away). Analysts expect earnings of $0.18 per share on revenue of $1.20B. Elanco Animal Health beat the earnings estimate in 7 of its last 8 reports, moving 10.1% on average across the report.

What is Elanco Animal Health’s 52-week high and low?

Elanco Animal Health’s 52-week high is $27.98 and its 52-week low is $19.40; it closed at $26.78 on Nov 13, 2026, +21.5% over the past year. Over the last five years the shares peaked at $33.20 on Nov 18, 2021.

Is Elanco Animal Health stock a buy right now?

Gekko describes the data; it does not make buy or sell recommendations. On the swing-trade checklist, 3 of the 6 items with data read as supportive (smart money, earnings risk and seasonality), 2 as mixed (trend and gekkoindex) and 1 as a headwind (fair value). The checklist is a description of current data, not a recommendation.

How this page works

During US trading hours the price at the top of the page is a delayed quote, refreshed every 15 minutes; everything else is rebuilt after each US market close. The GekkoIndex, Gekko Fair Value and the checklist are Gekko’s own, and the Gekko Brief is written by AI from this page’s data and checked against it before it is published. How Gekko’s data works →

See Elanco Animal Health the way Gekko members do

Every GekkoIndex reading, insider trade, options bet and Congress disclosure plotted on the chart, plus the 5,800-name screener and trade planning tools.

Join 1,475 other traders using Gekko

Start Your FREE 7 Day Trial → Every feature unlocked. No credit card required.